Speech dysfluency exacerbated by levodopa in Parkinson's disease

Elan D. Louis, Linda Winfield, Stanley Fahn, Blair Ford

Research output: Contribution to journalArticlepeer-review

44 Scopus citations


The role of dopamine in the modulation of speech fluency is complex. In this report we describe two patients with Parkinson's disease whose speech dysfluency was exacerbated by the administration of levodopa. In doing so, we extend the observation that dopaminergic mechanisms may be involved in the regulation of speech fluency. It is important for clinicians to recognize that, in some instances, dopaminergic replacement therapy may exacerbate an underlying dysfluency syndrome in PD.

Original languageEnglish (US)
Pages (from-to)562-565
Number of pages4
JournalMovement Disorders
Issue number3
StatePublished - May 2001
Externally publishedYes

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Speech dysfluency exacerbated by levodopa in Parkinson's disease'. Together they form a unique fingerprint.

Cite this